Fabric Genomics, Inc.

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the second quarter of 2025. “Crossing the $100 million revenue mark and delivering our fourth consecutive profitable quarter is a major milestone for GeneDx, putting us on a path for more growth at scale and enabling us to reach more patients while reducing unnecessary spend across the global healthcare system,” said Katherine Stueland, CEO of GeneDx. “Our strong second quarter performance was driven by our core business, underscoring its strength and resilience. These results, coupled with the ever-expanding opportunities ahead, including general pediatrics, demonstrate that we’re just beginning to deliver on the promise of how our technology can fundamentally change the way genomics can inform healthcare, shifting from reactive to proactive care.” Second Quarter 2025 Financial Results (Unaudited)1,2 Revenues Revenues grew to $102.7 million, an increase of 49% year-over-year. Exome and genome test revenue grew to $85.9 million, an increase of 69% year-over-year. Exome and genome volume Exome and genome test results volume grew to 23,102, an increase of 28% year-over-year. Exome and genome represented 41% of all tests, up from 31% in the second quarter of 2024. Gross margin Adjusted gross margin expanded to 71%, up from 62% in the second quarter of 2024. Total GAAP gross margin was 69%. Total GAAP gross margin was 69%. Operating expenses Adjusted total operating expenses were $57.8 million, representing 56% of revenue in the second quarter of 2025, compared to 65% of revenue in the second quarter of 2024. Total GAAP operating expenses were $61.9 million. Total GAAP operating expenses were $61.9 million. Net Income Adjusted net income was $15.0 million compared to an adjusted net loss of $2.0 million in the second quarter of 2024. GAAP net income was $10.8 million. GAAP net income was $10.8 million. Cash position Cash, cash equivalents, marketable securities and restricted cash was $135.5 million as of June 30, 2025. Cash flow for the second quarter 2025 primarily included: $33.2 million used to acquire Fabric Genomics, net of cash acquired, partially offset by; $10.4 million in cash generated from operations. $33.2 million used to acquire Fabric Genomics, net of cash acquired, partially offset by; $10.4 million in cash generated from operations. 1. Revenue and adjusted gross margin growth rates exclude revenue and costs of sales from the exited Legacy Sema4 diagnostic testing business. 2. Adjusted gross margin, adjusted total operating expenses and adjusted net income/(loss) are non-GAAP financial measures. See appendix for a reconciliation of GAAP to Non-GAAP figures presented. GeneDx Full Year 2025 Guidance GeneDx has raised certain elements of its full year 2025 guidance and expects to deliver: Metric Previous Guidance Updated Guidance Revenue $360 to $375 million $400 to $415 million Growth in exome and genome revenue 30% 48% to 52% Growth in exome and genome volume 30% 30% Adjusted gross margin 66% to 68% 68% to 71% Adjusted net income Positive each quarter and for full year Positive each quarter and for full year Second Quarter 2025 and Recent Business Highlights Strategic Expansion and Market Access Announced that the American Academy of Pediatrics now recommends exome and genome sequencing as first-tier tests for children with global developmental delay or intellectual disability, positioning pediatricians to offer exome and genome testing to their patients. Expanded commercial focus to include calling on providers treating children with inborn errors of immunity (IEI) , a group of nearly 500 genetic disorders that impair immune function. Accelerated adoption of exome and genome sequencing coverage by state Medicaid programs, bringing the total states covering exome or genome sequencing in the pediatric outpatient setting to 35 with the recent addition of Colorado and Maine, and the total states covering rapid genome sequencing in the neonatal intensive care unit (NICU) to 17 with the recent addition of Virginia, Ohio, and Oklahoma. Innovation & Clinical Leadership Acquired Fabric Genomics , enabling a hybrid centralized and decentralized model for delivering genomic insights globally. Published SeqFirst study in the Journal of Pediatrics , showing rapid genomic testing reduced time to diagnosis from about 10 months to 13 days. Published data in the American Journal of Medical Genetics underscoring GeneDx’s leadership in leveraging artificial intelligence (AI) to increase diagnostic yield and improve healthcare for patients with genetic conditions. Webcast and Conference Call Details GeneDx will host a conference call today, July 29, 2025, at 8:30 a.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the GeneDx investor relations website at https://ir.genedx.com/. Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our future performance, future operations, plans, objectives of management, and our market opportunity, including our expected full year 2025 reported revenue, volume, adjusted gross margin and adjusted net income. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to implement business plans, goals and forecasts, and identify and realize additional opportunities, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, (iv) our ability to pursue our new strategic direction, and (v) our ability to utilize our artificial intelligence tools that we use in our clinical interpretation platform. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 20, 2025, and our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025, filed with the SEC on April 30, 2025 and July 29, 2025, respectively, and other documents filed by us from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations. About GeneDx At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. For more information, please visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram. Volume & Revenue 1 2Q25 1Q25 4Q24 3Q24 2Q24 Volumes Whole exome, whole genome 23,102 20,562 20,676 19,262 18,017 Hereditary cancer 2,677 2,725 3,486 4,672 5,482 Other panels 29,894 28,228 30,115 35,095 34,204 Total 55,673 51,515 54,277 59,029 57,703 Revenue ($ millions) Whole exome, whole genome $ 85.9 $ 71.4 $ 78.8 $ 60.0 $ 50.7 Hereditary cancer 1.8 2.2 2.8 3.3 3.8 Other panels 12.1 12.1 12.3 13.8 13.3 Data information 2.0 1.4 1.4 (0.5 ) 1.1 Fabric Genomics 0.9 — — — — Total $ 102.7 $ 87.1 $ 95.3 $ 76.6 $ 68.9 Excludes volume and revenue from the exited Legacy Sema4 diagnostic testing business. Unaudited Select Financial Information (in thousands) Three months ended June 30, 2025 Three months ended June 30, 2024 GeneDx Other1 Total GeneDx Other1 Total Revenue $ 101,784 $ 908 $ 102,692 $ 68,924 $ 1,590 $ 70,514 Adjusted cost of services 29,964 244 30,208 26,523 145 26,668 Adjusted gross profit (loss) $ 71,820 $ 664 $ 72,484 $ 42,401 $ 1,445 $ 43,846 Adjusted gross margin % 70.6 % 73.1 % 70.6 % 61.5 % 90.9 % 62.2 % Other includes revenue and cost of services from the Legacy Sema4 diagnostic testing business for both periods presented. For the three months ended June 30, 2025, Other includes revenue and cost of services from Fabric Genomics. Three months ended June 30, 2025 Reported Depreciation and amortization Stock-based compensation expense Restructuring costs Change in FV of financial liabilities Other Adjusted Diagnostic test revenue $ 99,823 $ — $ — $ — $ — $ — $ 99,823 Other revenue 2,869 — — — — — 2,869 Total revenue 102,692 — — — — — 102,692 Cost of services 31,790 (1,389 ) (193 ) — — — 30,208 Gross profit (loss) 70,902 1,389 193 — — — 72,484 Gross margin 69.0 % 70.6 % Research and development 15,079 (209 ) (1,422 ) — — — 13,448 Selling and marketing 19,448 (1,298 ) (1,268 ) — — — 16,882 General and administrative 27,415 (3,295 ) (4,930 ) (73 ) — 8,342 27,459 Loss from operations 8,960 6,191 7,813 73 — (8,342 ) 14,695 Interest income (expense), net (817 ) — — — — 817 — Other income (expense), net 2,420 — — — (2,181 ) 49 288 Income tax benefit 246 — — — — (246 ) — Net income $ 10,809 $ 6,191 $ 7,813 $ 73 $ (2,181 ) $ (7,722 ) $ 14,983 Basic earnings per share* $ 0.38 $ 0.52 Diluted earnings per share* $ 0.36 $ 0.50 * Basic and diluted earnings per share are calculated based on 28,579,704 and 29,753,933 weighted average shares outstanding for the three months ended June 30, 2025, respectively. Three months ended June 30, 2024 Reported Depreciation and amortization Stock-based compensation expense Restructuring costs Change in FV of financial liabilities Other1 Adjusted Diagnostic test revenue $ 69,439 $ — $ — $ — $ — $ — $ 69,439 Other revenue 1,075 — — — — — 1,075 Total revenue 70,514 — — — — — 70,514 Cost of services 27,562 (808 ) (86 ) — — — 26,668 Gross profit (loss) 42,952 808 86 — — — 43,846 Gross margin 60.9 % 62.2 % Research and development 10,902 (211 ) (347 ) (35 ) — — 10,309 Selling and marketing 16,585 (1,225 ) (368 ) (63 ) — — 14,929 General and administrative 26,044 (2,974 ) (2,307 ) (150 ) — — 20,613 Loss from operations (10,579 ) 5,218 3,108 248 — — (2,005 ) Interest income (expense), net (894 ) — — — — 894 — Other income (expense), net (17,890 ) — — — 4,409 13,450 (31 ) Income tax benefit 190 — — — — (190 ) — Net loss $ (29,173 ) $ 5,218 $ 3,108 $ 248 $ 4,409 $ 14,154 $ (2,036 ) Basic loss per share* $ (1.10 ) $ (0.08 ) Diluted loss per share* $ (1.10 ) $ (0.08 ) * Basic and diluted loss per share are calculated based on 26,617,955 diluted weighted average shares outstanding for the three months ended June 30, 2024. Other represents interest expense, net, and income tax (expense) benefit for all periods presented. Other for the three months ended June 30, 2025 includes transaction costs related to the acquisition of Fabric Genomics. Other for the three months ended June 30, 2024 includes legal costs related to a legal settlement. GeneDx Holdings Corp. Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) June 30, 2025 (Unaudited) December 31, 2024 Assets: Current assets: Cash and cash equivalents $ 74,120 $ 85,212 Marketable securities 60,438 55,973 Accounts receivable 48,028 37,629 Inventory, net 11,932 10,650 Prepaid expenses and other current assets 10,319 8,504 Total current assets 204,837 197,968 Operating lease right-of-use assets 24,978 25,613 Property and equipment, net 40,120 32,893 Goodwill 12,926 — Intangible assets, net 176,689 158,600 Other assets1 4,313 4,306 Total assets $ 463,863 $ 419,380 Liabilities and Stockholders’ Equity: Current liabilities: Accounts payable and accrued expenses $ 49,239 $ 30,983 Short-term lease liabilities 3,083 3,336 Other current liabilities 19,084 20,498 Total current liabilities 71,406 54,817 Long-term debt, net of current portion 51,683 51,913 Long-term lease liabilities 59,619 60,919 Other liabilities 3,275 5,519 Deferred taxes 747 965 Total liabilities 186,730 174,133 Stockholders’ Equity: Preferred stock — — Class A common stock 2 2 Additional paid-in capital 1,624,513 1,596,889 Accumulated deficit (1,348,194 ) (1,352,474 ) Accumulated other comprehensive income 812 830 Total stockholders’ equity 277,133 245,247 Total liabilities and stockholders’ equity $ 463,863 $ 419,380 Other assets includes $990 thousand of restricted cash as of both June 30, 2025 and December 31, 2024. GeneDx Holdings Corp. Condensed Consolidated Statements of Operations (Unaudited) (in thousands, except share and per share amounts) Three months ended June 30, Six months ended June 30, 2025 2024 2025 2024 Revenue Diagnostic test revenue $ 99,823 $ 69,439 $ 185,582 $ 130,543 Other revenue 2,869 1,075 4,225 2,393 Total revenue 102,692 70,514 189,807 132,936 Cost of services 31,790 27,562 60,429 52,573 Gross profit 70,902 42,952 129,378 80,363 Research and development 15,079 10,902 27,656 22,469 Selling and marketing 19,448 16,585 37,764 32,670 General and administrative 27,415 26,044 59,549 49,463 Income (loss) from operations 8,960 (10,579 ) 4,409 (24,239 ) Non-operating income (expenses), net Change in fair value of warrants and contingent liabilities 2,181 (4,409 ) 1,081 (10,510 ) Interest expense, net (817 ) (894 ) (1,457 ) (1,491 ) Other income (expense), net 239 (13,481 ) 448 (13,444 ) Total non-operating income (expense), net 1,603 (18,784 ) 72 (25,445 ) Income (loss) before income taxes 10,563 (29,363 ) $ 4,481 $ (49,684 ) Income tax benefit (expense) 246 190 (201 ) 272 Net income (loss) $ 10,809 $ (29,173 ) $ 4,280 $ (49,412 ) Weighted average shares outstanding of Class A common stock - Basic 28,579,704 26,617,955 28,365,018 26,340,063 Earnings (loss) per share, Class A common stock- Basic $ 0.38 $ (1.10 ) $ 0.15 $ (1.88 ) Weighted average shares outstanding of Class A common stock - Diluted 29,753,933 26,617,955 29,642,555 26,340,063 Earnings (loss) per share, Class A common stock- Diluted $ 0.36 $ (1.10 ) $ 0.14 $ (1.88 ) GeneDx Holdings Corp. Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands) Six months ended June 30, 2025 2024 Operating activities Net income (loss) $ 4,280 $ (49,412 ) Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Depreciation and amortization expense 11,869 10,466 Stock-based compensation expense 11,796 2,657 Change in fair value of warrants and contingent liabilities (1,081 ) 10,510 Deferred tax expense (benefit) 202 (272 ) Provision for excess and obsolete inventory 123 109 Legal reserves — 13,450 Change in third party payor reserves 5,014 1,066 Other 1,387 1,738 Change in operating assets and liabilities: Accounts receivable (9,889 ) 6,622 Inventory (1,404 ) (1,654 ) Accounts payable and accrued expenses 7,199 (10,871 ) Other assets and liabilities (8,894 ) (5,327 ) Net cash provided by (used in) operating activities 20,602 (20,918 ) Investing activities Acquisition of business, net of cash acquired (33,195 ) — Purchases of property and equipment (8,498 ) (1,795 ) Purchases of marketable securities (30,770 ) (29,381 ) Proceeds from sales of marketable securities — 598 Proceeds from maturities of marketable securities 26,705 8,720 Net cash used in investing activities (45,758 ) (21,858 ) Financing activities Proceeds from offerings, net of issuance costs 13,766 — Proceeds from issuance of common stock pursuant to employee stock purchase plan 1,262 — Exercise of stock options 800 161 Long-term debt principal payments (602 ) — Finance lease principal payments (1,162 ) (990 ) Net cash provided by (used in) financing activities 14,064 (829 ) Net decrease in cash, cash equivalents and restricted cash (11,092 ) (43,605 ) Cash, cash equivalents and restricted cash, at beginning of period 86,202 100,668 Cash, cash equivalents and restricted cash, at end of period (1) $ 75,110 $ 57,063 Supplemental disclosures of cash flow information Cash paid for interest $ 3,210 $ 4,033 Cash paid for taxes $ 920 $ 557 Stock consideration paid pursuant to exercise of Perceptive warrant $ — $ 12,586 Purchases of property and equipment in accounts payable and accrued expenses $ 5,752 $ 501 Assets acquired under capital lease obligations $ — $ 689 Cash, cash equivalents and restricted cash at June 30, 2025 excludes marketable securities of $60.4 million.

For Illumina, its former employees are both a boon and a problem. In the 27 years since its founding, the DNA sequencing company unlocked new frontiers in biology, medicine and business. In doing so, it also spawned an entire ecosystem of new companies. Illumina veterans have founded more than 70 businesses, based on interviews, a review of LinkedIn pages and a crowdsourced list by former employees. These companies have raised $5.2 billion in venture capital, according to an Endpoints News tally of PitchBook data. Many of them buy Illumina’s gene-reading technology. But increasingly, the sequencing giant’s offspring are building machines and applications that compete with it. “Illumina no longer controls the ecosystem,” said John Stuelpnagel, who held executive roles at the company from 1998 to 2009. The year of his departure, he co-founded the genomics software company Fabric Genomics, and sits on the boards of several other firms in the industry. Many ex-Illumina companies remain close to their former employer, both professionally and geographically in San Diego, which has become a genomics hub thanks to Illumina. The intertwined relationship contrasts with perhaps the most well-known corporate lineage story. The “PayPal mafia” — including Elon Musk and Reid Hoffman — split off into unrelated ventures like Tesla and LinkedIn. Unlike the PayPal alumni, some of Illumina’s former employees call themselves the “Illumina diaspora.” The club includes Element Biosciences, Cellanome and Scale Biosciences. Such companies are doing much more than standard DNA sequencing, fueling a shift in the industry that has prompted Illumina to expand into products that analyze a wider set of biological data. “The market is really changing, and our strategy at Illumina is changing too to adapt,” Illumina’s chief technology officer Steven Barnard said in an interview with Endpoints in April. Illumina has not always managed its evolution well. In 2021, the company acquired Grail, which had been spun off from Illumina five years earlier. The $8 billion acquisition, part of Illumina’s bet on the early-detection cancer market, encountered regulatory pushback and ended in executive turnover, shareholder lawsuits and ultimately a divestiture of Grail. After retrenching, the company is navigating a new era with its former employees as both its customers and its fiercest competition. Illumina helped slash the cost of sequencing a human genome from billions of dollars to just a couple hundred dollars. That opened up a wide range of applications, from prenatal testing to cancer diagnostics. As the market matured, the company could only cover so much territory, leaving opportunities for its former employees to pursue, along with a playbook. Jay Flatley, who was Illumina’s CEO from 1999 to 2016, said the company taught operational and strategic discipline — qualities that have made ex-employees bankable as founders and leaders. Former Illumina employees are the CEOs of about 30 companies, according to data compiled by company alumni and Endpoints. “People who hire CEOs of startups want somebody who is not necessarily just an inventor of technology, but has the ability to build the company,” Flatley said. Among the early departures was Helmy Eltoukhy, who co-founded Guardant Health in 2012 to build cancer detection tests — an area Illumina wasn’t focused on at the time. Once DNA sequencing costs plummeted, there were “diminishing returns,” said Eltoukhy, Guardant’s co-CEO. “Focusing on true clinical applications that could truly solve human health challenges was something that I found more fulfilling.” Illustrating the rise of ex-Illumina companies, Guardant’s valuation has steadily increased since going public in 2018 and the company is now worth $4.7 billion. During that time frame, Illumina’s valuation has gone from $44 billion to $13 billion. In 2023, Illumina and Guardant settled a lawsuit that accused Guardant of stealing trade secrets. As part of the settlement, the companies have shared samples to advance cancer research, and inked a long-term supply agreement. But legal tensions between Illumina and some of its alumni are far from over. Some ex-employees have reimagined the DNA sequencing process that makes up Illumina’s core market. One of the most prominent challengers is Element Biosciences, founded in 2017 by former Illumina scientists. Earlier this month, Illumina sued Element, accusing it of using proprietary technology. Element said in a statement that it is “proud of its strong history of innovation” and plans to defend itself in court. Besides Element, drug giant Roche has poached Illumina employees to develop its sequencing machine that was invented by scientists without Illumina ties. Roche anticipates a limited commercial release in 2026, and eventually, a larger rollout is planned. At one point, Illumina faced an executive exodus, though it appears that’s no longer the case. Voluntary employee turnover at the director level and above stood at 6% in 2023, down from 17% in 2021, according to Illumina’s most recent corporate and social responsibility report. Shawn Baker, a former Illumina employee who runs the consulting firm SanDiegOmics, said Illumina’s struggles after the Grail deal likely contributed to departures, though it’s also natural for employees to split off from a maturing company. “The question is, ‘How positive is this for Illumina?’ Probably some positive, some negative,” Baker said. “For employees who went away and founded a successful company, that could have been an internal project if Illumina had funded it.” Barnard said one reason he’s stayed with the company for 27 years is that its innovative spirit is still intact. Specifically, a large chunk of each year is set aside for employees to dream up new ideas and decide which ones to tackle. “In many organizations, you never give people the freedom to do that,” Barnard said. “It’s a bit of a cliché to say that innovation dies as a company gets bigger. It certainly does happen. But we still run it like a startup, right? So that urgency and innovation is seen when getting a cup of coffee or sitting at lunch.” While Illumina faces competition from its diaspora, the company is also harnessing it. Companies founded by ex-Illumina staffers often use the company’s sequencers to derive biological insights — or their technologies complement Illumina’s offerings. “What we do ought to drive more sequencing, and Illumina is at the top of that list,” said Omead Ostadan, a former Illumina employee and the CEO of Cellanome. The company, founded in 2020, developed a platform to measure cell behaviors. And in 2016, Illumina launched Illumina Ventures, which invests in startups aligned with its mission. The fund operates independently, and Illumina doesn’t have control over its investment decisions. But the effort reflects the company’s broader strategy of growing the sequencing market while tying new ventures to Illumina’s platform. One of these investees, the cell analysis company Fluent BioSciences, ended up being acquired by Illumina in 2024 as part of the company’s expansion beyond DNA sequencing. Illumina, long the pick-and-shovel provider with its DNA sequencers, is increasingly moving toward the gold of downstream applications, such as pan-cancer diagnostics. Some of its markets, once too small for the company to pursue, now have the potential to be high-growth vehicles. At times, that has the sequencing giant bumping into its diaspora. In February, the company announced it was further expanding into multiomics — a catch-all for decoding not just DNA, but also RNA, proteins, and other parts of biology. The idea is to make the most of the customers Illumina already has by selling them kits and instruments that add multiomic functions to its DNA sequencers. “We want to start using that power of our install base,” said Barnard, Illumina’s chief technology officer. But that means competing with alumni. Scale Biosciences, founded in 2020, specializes in single-cell genomics to understand cellular diversity — and now Illumina is encroaching into its territory. Scale CEO Giovanna Prout , who worked at Illumina from 2005 to 2017, said that in overlapping areas, her former employer has the advantage of commercial scale and name recognition, but her team has the advantage of nimbleness. “Customers need to see their performance, and we’re not slowed down by 35 people in the room and bureaucracy and long decision-making,” Prout said. Editor’s note: This article was updated to clarify Scale Biosciences’ specialization.

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the publication of a new article in the American Journal of Medical Genetics, demonstrating GeneDx’s leadership in applying artificial intelligence (AI) to accelerate and enhance genetic diagnostics. The article was published as part of an essay collection written by global experts addressing how AI is shaping, and will continue to shape, the future of medical genetics. The GeneDx-authored article, “AI in the Clinical Genomics Laboratory,” underscores the promise of harnessing AI to increase diagnostic yield, reduce manual workflows, and scale precision medicine for all patients with suspected genetic conditions. “AI can be a powerful tool to enhance the expertise of clinical genetics professionals,” said Tim Laurent, Director of AI at GeneDx. “From extracting phenotypic data from clinical notes to prioritizing genetic variants, we’re building intelligent, transparent systems that work hand-in-hand with our expert team of geneticists to accelerate diagnosis while ensuring accuracy.” With one of the world’s most comprehensive and clinically curated genomic and phenotypic datasets, GeneDx has a durable strategic advantage in training and deploying AI models for diagnostics. This depth of data enables faster, more accurate diagnoses, and builds on a foundation of agile AI infrastructure, which allows GeneDx to drive transformational scale and efficiency across an already differentiated interpretation and analysis platform. As the cost of genomic sequencing continues to decline and guidelines increasingly recommend exome and genome sequencing as standard of care, the volume of patients eligible for testing is expected to outpace the capacity of the current genetics workforce. GeneDx is strategically leveraging its unique dataset and cutting-edge AI technologies to close that gap. “AI is not just a tool for efficiency and streamlining operations, it’s an engine for discovery,” said Bryan Dechairo, Chief Operating Officer at GeneDx. “Because AI is only as powerful as the data it's trained on, GeneDx is uniquely positioned to embed AI across our business – from clinical interpretation to lab operations – to meet the growing demand for genomic testing and deliver answers at scale.” The publication comes on the heels of GeneDx’s acquisition of Fabric Genomics, a leader in AI interpretation. Together, GeneDx and Fabric Genomics are ushering in the next era of genomic medicine, enabling decentralized testing powered by centralized intelligence to set the standard of care across the globe. About GeneDx: At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest, rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. For more information, please visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram. Forward Looking Statements This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to implement business combinations, plans, goals and forecasts, and identify and realize additional opportunities, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, (iv) our ability to pursue our new strategic direction, and (v) our ability to enhance our artificial intelligence tools that we use in our clinical interpretation platform. The foregoing list of factors is not exhaustive. A further list and description of risks, uncertainties and other matters can be found in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and other documents filed by us from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations.